Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors

  • Authors: Eva Klopocki, Glen Kristiansen, Peter J. Wild, Irina Klaman, Esmeralda Castanos-Velez, Gad Singer, Robert Stöhr, Ronald Simon, Guido Sauter, Haike Leibiger, Lutz Essers, Birgit Weber, Klaus Hermann, André Rosenthal, Arndt Hartmann, Edgar Dahl
  • View Affiliations

  • Published online on: Wednesday, September 1, 2004
  • Pages: 641-649
  • DOI: 10.3892/ijo.25.3.641

Abstract

Aberrant activation of the Wnt signaling pathway plays an important role in the development of solid tumors such as breast and colon cancer. Secreted Frizzled-related protein 1 (SFRP1) is a negative regulator of the Wnt pathway. It has been described that SFRP1 mRNA is strongly down-regulated in breast cancer and a putative tumor suppressor function has been postulated. We have generated and characterized an SFRP1 specific antibody to analyze its expression on protein level and to investigate the association of SFRP1 expression with clinicopathological parameters and patient survival. Analysis of >2000 invasive breast tumors and 56 carcinoma in situ revealed similar frequencies of SFRP1 loss in these tumors (46% and 43% respectively). Therefore, we propose that loss of SFRP1 expression is an early event in breast tumorigenesis. SFRP1 expression was inversely correlated with tumor stage (p<0.001) but not with tumor grade (p=0.14) or lymph node status (p=0.84). Performing a multivariate analysis we could confirm the association between tumor stage and SFRP1 expression (p=0.029). In particular, loss of SFRP1 expression in early stage breast tumors (pT1) was associated with poor prognosis (p=0.04). In conclusion, expression of SFRP1 is commonly lost in breast cancer. SFRP1 expression might be useful as a novel prognostic marker in early stage breast cancer.
Journal Cover

September 2004
Volume 25 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

2013 Impact Factor: 2.773
Ranked #30/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Klopocki, E., Kristiansen, G., Wild, P., Klaman, I., Castanos-Velez, E., Singer, G., Stöhr, R., Simon, R., Sauter, G., Leibiger, H., Essers, L., Weber, B., Hermann, K., Rosenthal, A., Hartmann, A., & Dahl, E. (2004). Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. International Journal of Oncology, 25(3), 641-649.
MLA
Klopocki, Kristiansen, Wild, Klaman, Castanos-Velez, Singer, Stöhr, Simon, Sauter, Leibiger, Essers, Weber, Hermann, Rosenthal, Hartmann, and Edgar Dahl. "Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors." International Journal of Oncology International Journal of Oncology 25.3 (2004): 641-649.
Chicago
Klopocki, Kristiansen, Wild, Klaman, Castanos-Velez, Singer, Stöhr, Simon, Sauter, Leibiger, Essers, Weber, Hermann, Rosenthal, Hartmann, and Edgar Dahl. "Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors." International Journal of Oncology International Journal of Oncology 25 no. 3 (2004): 641-649.